


Hexima Limited (ASX:HXL) Revenue
Biotechnology Research • Melbourne, Victoria, Australia • 1-10 Employees
Hexima Limited (ASX:HXL) revenue & valuation
| Annual revenue | $4,002,009 |
| Revenue per employee | $572,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $12,900,000 |
| Total funding | $1,100,000 |
Key Contacts at Hexima Limited (ASX:HXL)
Nicole Van Der Weerden
Non Executive Director
Justin Yap
Non Executive Director
Company overview
| Headquarters | Melbourne, Victoria, Australia |
| Phone number | +61398636477 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Fungal Pathogens, Onychomycosis, Antifungal Peptides |
| Founded | 1998 |
| Employees | 1-10 |
| Socials |
About Hexima Limited (ASX:HXL)
Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (formally HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Hexima Limited (ASX:HXL) Tech Stack
Discover the technologies and tools that power Hexima Limited (ASX:HXL)'s digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
Programming languages
Blogs
Page builders
Analytics
SEO
Cookie compliance
Tag managers
Reverse proxies
Caching
Frequently asked questions
4.8
40,000 users



